Literature DB >> 10574648

Omega-3 polyunsaturated fatty acids and ventricular fibrillation: the possible involvement of eicosanoids.

J S Charnock1.   

Abstract

Increased dietary omega-3 polyunsaturated fatty acids (PUFAs) reduce the incidence and severity of ventricular fibrillation (VF) in laboratory animals subjected to partial ischaemia and reduce the risk of cardiac arrest in humans after myocardial infarction. In whole animals there is considerable evidence which suggests that incorporation of these fatty acids into cardiac membrane phospholipids influences the production of a variety of eicosanoids having opposing arrhythmogenic or anti-arrhythmogenic properties, and that the balance of these actions is shifted in favour of an anti-arrhythmogenic state by feeding fish oil dietary supplements rich in omega-3 PUFA. However, differences in eicosanoid biosynthesis between species, between tissues of the same species and even between different intracellular sites within cells of the same tissue could influence experimental outcomes. The importance of further studies with the most appropriate whole animal models or tissues is emphasized, as is the difference between the structural integrity of cardiac muscle and cardiomyocytes in vitro.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10574648     DOI: 10.1054/plef.1999.0096

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  2 in total

1.  Effects of fluorine-containing opener of ATP-sensitive potassium channels, pinacidil-derivative flocalin, on cardiac voltage-gated sodium and calcium channels.

Authors:  Oleg I Voitychuk; Ruslan B Strutynskyi; Olexiy O Moibenko; Yaroslav M Shuba
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-09-08       Impact factor: 3.000

2.  Sarcolemmal cardiac K(ATP) channels as a target for the cardioprotective effects of the fluorine-containing pinacidil analogue, flocalin.

Authors:  Oleg I Voitychuk; Ruslan B Strutynskyi; Lev M Yagupolskii; Andrew Tinker; Olexiy O Moibenko; Yaroslav M Shuba
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.